– Finance and business development veteran and founding member of the CAMP4 leadership team –

CAMBRIDGE, Mass.–(BUSINESS WIRE)–CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNAs to upregulate genes and restore healthy expression, today announced the appointment of Kelly Gold as Chief financial director. Ms. Gold, who currently serves as CAMP4’s Chief Commercial Officer and Senior Vice President of Finance, will lead all financial and financial operations for the company and oversee relationships with financial institutions and investors.

This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20220419005098/en/

“Kelly is a savvy finance executive and experienced leader who has made significant contributions to the company, including playing a key role in raising $90 million in our funding to date and establishing the structure allowing CAMP4 to evolve into a mature and independent financial company. organization,” said Josh Mandel-Brehm, CEO of CAMP4. “His deep skill set and intimate understanding of all aspects of our business and strategy will continue to be a tremendous asset to CAMP4 as we continue to advance our portfolio of precise and programmable therapeutic candidates targeting regulatory RNA. and expand our discovery platform.”

Ms. Gold joined CAMP4 in 2017 and has held positions of increasing responsibility leading the business development and finance functions. She has in-depth knowledge of CAMP4’s financial organization and experience in leading business development, operations, accounting, investor relations and corporate communications functions.

Prior to joining CAMP4, Ms. Gold held various positions in corporate finance and business planning at Biogen, where she provided financial leadership for the company’s late-stage and commercialized rare disease programs. Prior to Biogen, Ms. Gold worked in the Latin American healthcare and investment banking groups at Deutsche Bank. Ms. Gold began her career as a mechanical engineer designing biocontainment systems for Biosafety Level 4 research facilities. She holds bachelor’s degrees in biochemistry and mechanical engineering from Queen’s University in Ontario, as well as an MBA from MIT Sloan School of Management.

“As an early member of the CAMP4 team and someone who has always enjoyed operating at the intersection of science and business, I am excited to continue to grow the business as CFO and ensure that we are equipped and successful in our next phase of growth,” said Ms. Gold. “We are pioneering a new approach to regulating genes in a very specific way that has enormous potential benefits for patients with genetic diseases and potential value for our investors.”

CAMP4 combines its proprietary RNA Activation Platform (RAP) with state-of-the-art oligonucleotide technology to develop RNA actuators, precise and programmable therapies that uniquely upregulate gene expression at the transcriptional level. CAMP4’s approach targets a new class of RNAs known as regulatory RNAs (“regRNAs”) that control mRNA expression, making this approach applicable to any genetic disease in which a small increase in gene production can lead to significant therapeutic results. CAMP4’s current pipeline focuses on diseases for which oligonucleotides have been shown to be safe and effective, including CNS and liver diseases, with the potential to extend to a wide range of tissues.

About CAMP4 Therapeutics

At CAMP4, we are pioneering a new approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Proprietary knowledge of our RNA activation platform allows us to harness the power of RNA to upregulate gene expression and unlock the potential to create treatments for hundreds of diseases affecting million patients. Learn more about us at www.CAMP4tx.com and follow us @CAMP4tx.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220419005098/en/